RxDoctor Payments Data

Luis Zayas-Rodriguez, MD

Neurology · Clinton, TNNPI 1184823312

Payments from drug & device makers

$6,153in general payments, 2019–2025

Across 110 payments — averaging $55.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Medtronic$1K
  • Acadia Pharmaceuticals Inc$1K
  • AbbVie$414
  • Neurocrine Biosciences, Inc.$214
  • Amneal Pharmaceuticals LLC$183
  • plus $1K from 16 others

What the payments were for

  • Consulting fees$2634%
  • Speaking & faculty fees$84614%
  • Travel & lodging$2,11934%
  • Food & beverage$2,92548%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,153 in reported general payments places this provider in the 55th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$116,964
Medicare patients
353
Services billed
1,254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate47$397,312
AustedoDeutetrabenazine43$361,645
NuplazidPimavanserin Tartrate39$193,213
RytaryCarbidopa/Levodopa75$95,652
GocovriAmantadine Hcl24$73,332
MyrbetriqMirabegron75$37,973
BriviactBrivaracetam22$32,806
Carbidopa-LevodopaCarbidopa/Levodopa811$26,929
Nurtec OdtRimegepant Sulfate19$26,338
Lacosamide76$25,665
NeuproRotigotine20$15,899
Carbidopa-Levodopa ErCarbidopa/Levodopa308$12,789
GemtesaVibegron22$11,112
Aimovig AutoinjectorErenumab-Aooe11$9,140
Rivastigmine39$6,944

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$214$397,31247 claims
Teva Pharmaceuticals USA, Inc.Austedo$156$361,64543 claims
Acadia Pharmaceuticals IncNuplazid$1,171$193,21339 claims
Amneal Pharmaceuticals LLCRytary$183$95,65275 claims
MDD US Operations, LLCGocovri$114$73,33224 claims
UCB, Inc.Briviact, Neupro$92$48,70542 claims
PfizerNurtec Odt$20$26,33819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 361 neurology providers in Tennessee.

Other neurology in Clinton

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →